Keine Story von Trillium Therapeutics Inc. mehr verpassen.

Trillium Therapeutics Inc.

  • 05.11.2008 – 13:36

    Trillium Strengthens its Board of Directors

    Toronto, November 5 (ots/PRNewswire) - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans Dr. Michael Berendt and Dr. John Dietrich have joined its Board as independent directors. Trillium Chairman Dr. Michael Moore commented: "It is a great pleasure to welcome these two experienced biotech executives to the Board where they will enhance our capabilities in ...